Percent change was and is an embarrassing mistake

Journal of Rheumatology

Volumn 37, Issue 12, 2010, Pages 2448-2451

  Smythe, Hugh A ^a  

^a 2 Heathbridge Park ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INFLUENZA VACCINE; PLACEBO;

ACCURACY; BONE DENSITY; CALCULATION; COMPARATIVE STUDY; DRUG EFFICACY; EDITORIAL; HUMAN; MEDICAL STUDENT; MEDICATION ERROR; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUBLICATION; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ERRORS; STATISTICS AS TOPIC;

EID: 78649732114     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100943     Document Type: Editorial

References (10)

1. Leslie W. The importance of spectrum bias on bone density monitoring in clinical practice. Bone 2006;39:361-8.
2. Poon EG, Keohane CA, Yoon CS, Ditmore M, Bane A, Levtzion-Korach O, et al. Effect of bar-code technology on the safety of medication administration. N Engl J Med 2010;362:1698-707.
3. Deodhar A. When less is more. J Rheumatol 2010;37:1089-90.
4. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
5. Smythe HA, Bogoch ER. Common measures and analytic techniques provide flawed assessments of pain: modeled data, and hip replacement study. J Rheumatol 2008;35:2400-5.
6. Sackett DL, Cook RJ. Understanding clinical trials. What measures of efficacy should journals provide busy clinicians. BMJ 1994;309:755-6.
7. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
8. Gladman DD, Tom BDM, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis. II: Further considerations and a proposal - The PsA joint activity index. J Rheumatol 2010;37:2559-65.
9. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al, and the Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
10. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;21 Suppl 41:86-9.